Skip to content

Eur Neuropsychopharmacol

ISSN 0924-977x; 1873-7862;

8 papers in the library · 529 citations · publishing 2010-2026

Papers

Sort Most recent Most cited

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Eur Neuropsychopharmacol August 27, 2026 correction

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

DOI: 10.1016/j.euroneuro.2026.113860 (opens in new tab)

Psychedelics: The pathway to implementation in the European healthcare systems.

Eur Neuropsychopharmacol December 3, 2025

The integration of psychedelic therapies into European healthcare is a nuanced process that involves not only obtaining European Medicines Agency (EMA) approval but also successfully navigating Health Technology Assessment (HTA) evaluations across member states. After EMA approval, which focuses on the safety, efficacy, and quality of the therapeutic, HTA agencies assess these therapies for...

DOI: 10.1016/j.euroneuro.2025.11.007 (opens in new tab)

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

Eur Neuropsychopharmacol November 7, 2025 Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al. 12 citations

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

DOI: 10.1016/j.euroneuro.2025.09.011 (opens in new tab) Psychedelic therapy MDMA Therapy Psychedelic medicine Entheogenic therapy +12

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

Eur Neuropsychopharmacol May 20, 2016 Anna Rickli, Olivier D. Moning, Marius C. Hoener et al. 374 citations

The present study investigated interactions between the novel psychoactive tryptamines DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT at monoamine receptors and transporters compared with the classic hallucinogens lysergic acid diethylamide (LSD), psilocin, N,N-dimethyltryptamine (DMT), and mescaline. We investigated binding affinities at human monoamine receptors and determined...

DOI: 10.1016/j.euroneuro.2016.05.001 (opens in new tab)

LSD modulates music-induced imagery via changes in parahippocampal connectivity.

Eur Neuropsychopharmacol April 12, 2016 Mendel Kaelen, Leor Roseman, Joshua Kahan et al. 143 citations

Psychedelic drugs such as lysergic acid diethylamide (LSD) were used extensively in psychiatry in the past and their therapeutic potential is beginning to be re-examined today. Psychedelic psychotherapy typically involves a patient lying with their eyes-closed during peak drug effects, while listening to music and being supervised by trained psychotherapists. In this context, music is...

DOI: 10.1016/j.euroneuro.2016.03.018 (opens in new tab) LSD Lysergic acid diethylamide Hallucinogens Psychedelics +18